MCID: LYM024
MIFTS: 48

Lymphatic System Disease

Categories: Cardiovascular diseases, Fetal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphatic System Disease

MalaCards integrated aliases for Lymphatic System Disease:

Name: Lymphatic System Disease 12 15 17
Lymphatic Diseases 42 43 71
Adenopathy 12 15
Disorder of Lymph Node and Lymphatics 12
Abnormality of the Lymphatic System 29
Disorder of Lymphatic System 12
Disorder of Lymphoid System 12
Disease of Lympoid System 12
Lympoid System Disease 12
Lymphatic Disorder 12
Lymphatic Disease 12
Lymphangiopathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:75
MeSH 43 D008206
SNOMED-CT 67 3305006
UMLS 71 C0024228

Summaries for Lymphatic System Disease

MedlinePlus : 42 The lymphatic system is a network of tissues and organs. It is made up of Lymph - a fluid that contains white blood cells that defend against germs Lymph vessels - vessels that carry lymph throughout your body. They are different from blood vessels. Lymph nodes - glands found throughout the lymph vessels. Along with your spleen, these nodes are where white blood cells fight infection. Your bone marrow and thymus produce the cells in lymph. They are part of the system, too. The lymphatic system clears away infection and keeps your body fluids in balance. If it's not working properly, fluid builds in your tissues and causes swelling, called lymphedema. Other lymphatic system problems can include infections, blockage, and cancer.

MalaCards based summary : Lymphatic System Disease, also known as lymphatic diseases, is related to lymphadenitis and histiocytosis, and has symptoms including edema, axillary lymph node pain and axillary lymph node tenderness. An important gene associated with Lymphatic System Disease is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Ganciclovir and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include lymphatic system, b cells and t cells.

Disease Ontology : 12 An immune system disease that is located in the lymphatic system.

Wikipedia : 74 Lymphatic disease is a class of disorders which directly affect the components of the lymphatic... more...

Related Diseases for Lymphatic System Disease

Diseases in the Lymphatic System Disease family:

Rare Lymphatic System Anomaly

Diseases related to Lymphatic System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 724)
# Related Disease Score Top Affiliating Genes
1 lymphadenitis 33.4 SERPINA3 ICOSLG CD4 CCR6
2 histiocytosis 32.8 U2AF1 TNFRSF8 SERPINA3 CD1C CD1A CCR6
3 mycosis fungoides 32.8 TNFRSF8 CD1C CD1B CD1A CCR6
4 sarcoidosis 1 31.9 SERPINA3 ICOSLG CD8A CD40LG CD4 CCR6
5 pharyngitis 31.6 CD8A CD40LG CD4 CD1A
6 cat-scratch disease 31.6 CD68 CD40LG CD4
7 histoplasmosis 31.4 CD8A CD40LG CD4 CCR6
8 lymphoma, hodgkin, classic 31.3 TNFRSF8 IRF4 ICOSLG CD68 CCR6
9 syphilis 31.3 CD8A CD40LG CD4 CCR6
10 tularemia 31.2 CD8A CD40LG CD4
11 squamous cell carcinoma, head and neck 31.2 U2AF1 MIR17 MIR150 ICOSLG H2AC18 CD8A
12 immune deficiency disease 31.1 TNFRSF8 IRF4 ICOSLG H2AC18 CD40LG CD4
13 exanthem 31.1 ICOSLG H2AC18 CD8A CD40LG CD4 CCR6
14 mycobacterium tuberculosis 1 31.0 TNFRSF8 SERPINA3 ICOSLG H2AC18 CD8A CD4
15 coccidioidomycosis 31.0 CD40LG CD4 CCR6
16 polyclonal hypergammaglobulinemia 30.8 SERPINA3 CD8A CD40LG CD4 CD1E CD1C
17 common variable immunodeficiency 30.8 TNFRSF8 IRF4 ICOSLG CD40LG
18 systemic lupus erythematosus 30.8 MIR150 IRF4 ICOSLG H2AC18 CD8A CD40LG
19 sialadenitis 30.8 ICOSLG CD8A CD4 CCR6
20 granulomatous hepatitis 30.8 CD8A CD40LG CD4
21 bronchopneumonia 30.8 SERPINA3 CD8A CD40LG CD4
22 persistent generalized lymphadenopathy 30.8 SERPINA3 PGLS CD40LG
23 herpes zoster 30.8 ICOSLG CD8A CD40LG CD4
24 cervix carcinoma 30.8 U2AF1 SERPINA3 MIR150 H2AC18
25 oral candidiasis 30.8 CD8A CD4 CCR6
26 adult t-cell leukemia 30.7 TNFRSF8 IRF4 CD4 CCR6
27 granulomatosis with polyangiitis 30.7 ICOSLG CD40LG CD4 CCR6
28 langerhans cell histiocytosis 30.7 U2AF1 CD68 CD1C CD1A CCR6
29 reticulosarcoma 30.7 TNFRSF8 SERPINA3 CD68
30 pericardial effusion 30.7 TNFRSF8 CD40LG CD4
31 primary syphilis 30.7 CD40LG CD4
32 severe cutaneous adverse reaction 30.7 CD8A CD40LG CD4
33 pfeiffer syndrome 30.7 TNFRSF8 H2AC18 CD8A CD40LG CD4 CCR6
34 peripheral nervous system disease 30.7 SERPINA3 ICOSLG H2AC18 CD8A CD40LG CD4
35 leprosy 3 30.6 CD8A CD40LG CD4 CD1E CD1C CD1B
36 lymph node disease 30.6 SERPINA3 PGLS ICOSLG CD8A CD40LG CD4
37 primary biliary cirrhosis 30.6 MIR17 MIR150 CD40LG CD4 CD1D
38 lymphoid interstitial pneumonia 30.6 CD8A CD40LG CD4 CD1E CD1D CD1C
39 cellulitis 30.6 ICOSLG CD8A CD40LG CD4 CCR6
40 interstitial pneumonitis, desquamative, familial 30.5 CD1E CD1A
41 leukemia, acute lymphoblastic 30.5 U2AF1 MIR17 IRF4 H2AC18 CCR6
42 pancytopenia 30.5 UNC13D U2AF1 SERPINA3 IRF4 CD8A CD68
43 intestinal disease 30.5 SERPINA3 MIR17 MIR150 ICOSLG H2AC18 CCR6
44 laryngeal disease 30.5 MIR17 H2AC18 CCR6
45 autoimmune lymphoproliferative syndrome 30.5 UNC13D ICOSLG H2AC18 CD8A CD40LG CD4
46 lymphoma, non-hodgkin, familial 30.4 U2AF1 TNFRSF8 SERPINA3 MIR17 IRF4 ICOSLG
47 leukemia, chronic lymphocytic 30.4 U2AF1 TNFRSF8 MIR17 MIR150 IRF4 ICOSLG
48 myeloma, multiple 30.2 U2AF1 TNFRSF8 MIR17 IRF4 ICOSLG H2AC18
49 reticulum cell sarcoma 30.1 TNFRSF8 CD4
50 pulmonary sarcoidosis 11.4

Graphical network of the top 20 diseases related to Lymphatic System Disease:



Diseases related to Lymphatic System Disease

Symptoms & Phenotypes for Lymphatic System Disease

UMLS symptoms related to Lymphatic System Disease:


edema, axillary lymph node pain, axillary lymph node tenderness

Drugs & Therapeutics for Lymphatic System Disease

Drugs for Lymphatic System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
3 Antiviral Agents Phase 4
4 Vaccines Phase 4
5 Ganciclovir triphosphate Phase 4
6 Anti-Infective Agents Phase 4
7 Antibiotics, Antitubercular Phase 4
8 Anti-Bacterial Agents Phase 4
9
rituximab Approved Phase 3 174722-31-7 10201696
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
12
Carmustine Approved, Investigational Phase 3 154-93-8 2578
13
Melphalan Approved Phase 3 148-82-3 4053 460612
14
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
15 Antimetabolites Phase 3
16 Immunosuppressive Agents Phase 3
17 Antibodies, Monoclonal Phase 3
18 Alkylating Agents Phase 3
19 Immunoglobulins Phase 3
20 Antibodies Phase 3
21 Antineoplastic Agents, Immunological Phase 3
22 Antirheumatic Agents Phase 3
23 Topoisomerase Inhibitors Phase 3
24 Etoposide phosphate Phase 3
25 Protein Kinase Inhibitors Phase 3
26 Imatinib Mesylate Phase 3 220127-57-1 123596
27
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
28
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
29
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
30
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
31
Blinatumomab Approved, Investigational Phase 2 853426-35-4
32
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
33
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
34
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
35
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
37
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
38
Zanubrutinib Approved, Investigational Phase 1, Phase 2 1691249-45-2
39
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
40
Sodium citrate Approved, Investigational Phase 2 68-04-2
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
43
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
44
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
45
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
46
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
47
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
48
Vinblastine Approved Phase 2 865-21-4 13342 241903
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Ifosfamide Approved Phase 2 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Intracavitary Manual Lymphatic Drainage Versus Conventional Treatment in the Prevention of Perineal Trauma During Labor. Completed NCT02960841 Phase 4
2 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
3 Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction Completed NCT00119067 Phase 4
4 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
5 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
6 Randomized Controlled Trial Short Antibiotic Therapy (3-Day) Versus Long Antibiotic Therapy (7-Day) in Odontology-Stomatology: Impact on the Resistance of Oral Streptococci Terminated NCT00764062 Phase 4 Amoxicillin
7 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
8 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer Active, not recruiting NCT01242800 Phase 3
9 A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Terminated NCT01650805 Phase 3 ponatinib;imatinib (Gleevec/ Glivec)
10 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
11 Efficacy of Monitoring Strategies Following Definitive Therapy for Locally Advanced Head and Neck Cancer: A Randomized, Phase III Trial of PET/CT vs. CT Surveillance Terminated NCT02655068 Phase 3
12 Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications (Therapeutische Bewertung Von Armkompressionsstrümpfen für Lymphatische Indikationen BF09-PH-01) Unknown status NCT01318785 Phase 2
13 An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Completed NCT01022996 Phase 2 Everolimus (RAD001)
14 A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT00435916 Phase 2 SGN-40
15 A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia Completed NCT00283101 Phase 1, Phase 2 SGN-40 (anti-huCD40 mAb)
16 An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01209286 Phase 2
17 Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer Completed NCT00791154 Phase 1, Phase 2 AMG 479;Etoposide;Placebo;AMG 102;Carboplatin;Cisplatin
18 A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST) Completed NCT01207388 Phase 2 Blinatumomab
19 A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy Completed NCT03067610 Phase 2 chemotherapy
20 A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
21 Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation Completed NCT03135535 Phase 2
22 A Single-Arm Multicenter Phase II Study Preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01471782 Phase 1, Phase 2
23 An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01466179 Phase 2
24 A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs) Completed NCT01667133 Phase 1, Phase 2 ponatinib - Phase 1;ponatinib - Phase 2
25 An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT01741792 Phase 2 Blinatumomab
26 A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen. Recruiting NCT02499627 Phase 2 Brentuximab Vedotin;Bendamustine
27 Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients Recruiting NCT02497131 Phase 2 Brentuximab Vedotin
28 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Recruiting NCT03744676 Phase 2
29 A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation Recruiting NCT03373019 Phase 2 Chidamide combined with R-GDP
30 Third Party Anti-viral Cytotoxic T-cells (CTLs) for Treatment of Viral Infections in Immunocompromised Patients Recruiting NCT02532452 Phase 2
31 A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting NCT03162536 Phase 1, Phase 2 ARQ 531;ARQ 531
32 SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype Recruiting NCT03713320 Phase 2 Cobomarsen;Vorinostat
33 Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations Recruiting NCT02335242 Phase 2 Sildenafil 20 mg tablets
34 Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting NCT03349450 Phase 2 Cyclophosphamide 50mg
35 Donor-Derived Anti-viral CTLs for Treatment of Viral Infections After Allogeneic Stem Cell Transplant Recruiting NCT02048332 Phase 1, Phase 2
36 Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group Recruiting NCT03264131 Phase 2 Brentuximab Vedotin;CHEP
37 Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma Recruiting NCT02690545 Phase 1, Phase 2
38 A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies Active, not recruiting NCT02265731 Phase 1, Phase 2 azacitadine;venetoclax;rituximab / IDEC-C2B8;rituximab / IDEC-C2B8
39 A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia Active, not recruiting NCT02733042 Phase 1, Phase 2 Durvalumab;Lenalidomide;Rituximab;Ibrutinib;Bendamustine
40 A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women With Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis Active, not recruiting NCT00881361 Phase 2 systemic chemotherapy
41 A Phase 1 B/2, Open-label, Single Arm, Multi-cohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-hodgkin's Lymphoma (B-NHL) Active, not recruiting NCT03743246 Phase 1, Phase 2 JCAR017;Lymphodepleting;Fludarabine;Cyclophosphamide
42 PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study Enrolling by invitation NCT03837457 Phase 2 Cobomarsen
43 A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Terminated NCT00529503 Phase 2 SGN-40;placebo;rituximab;etoposide;carboplatin;ifosfamide
44 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome Terminated NCT01513317 Phase 2 Siltuximab;Placebo;Best supportive care (BSC)
45 An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b Terminated NCT02855359 Phase 2 denintuzumab mafodotin;rituximab;cyclophosphamide;doxorubicin;vincristine;prednisone
46 A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant Terminated NCT02592876 Phase 2 denintuzumab mafodotin;rituximab;ifosfamide;carboplatin;etoposide
47 A Phase II Study of SGN-30 in Combination With CHOP in Anaplastic Large Cell Lymphoma Terminated NCT00365274 Phase 2 Cyclophosphamide;Doxorubicin hydrochloride;vincristine sulfate;prednisone;SGN-30
48 A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab Terminated NCT01013961 Phase 2
49 A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site Terminated NCT00148135 Phase 2 Carboplatin;Gemcitabine;Capecitabine
50 Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL) Terminated NCT01390584 Phase 2 ABVD Induction;Escalated BEACOPP;Standard BEACOPP

Search NIH Clinical Center for Lymphatic System Disease

Cochrane evidence based reviews: lymphatic diseases

Genetic Tests for Lymphatic System Disease

Genetic tests related to Lymphatic System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Lymphatic System 29

Anatomical Context for Lymphatic System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Lymphatic System Disease:

19
Lymphatic System

MalaCards organs/tissues related to Lymphatic System Disease:

40
B Cells, T Cells, Lymph Node, Bone, Lung, Thymus, Bone Marrow

Publications for Lymphatic System Disease

Articles related to Lymphatic System Disease:

(show top 50) (show all 130)
# Title Authors PMID Year
1
Acute Appendicitis or Lymphoid Hyperplasia: How to Distinguish More Safely? 42
31500858 2019
2
Intramammary lymph nodes: normal and abnormal multimodality imaging features. 42
31322919 2019
3
Nontuberculous lymphadenitis in children: What management strategy? 42
31039497 2019
4
Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review. 61
31549367 2020
5
Intussusceptive Lymphangiogenesis in Lymphatic Malformations/Lymphangiomas. 61
31228317 2019
6
[Current Therapies in Superficial Malignant Tumors]. 61
31610596 2019
7
Comprehensive analysis of Helicobacter pylori infection-associated diseases based on miRNA-mRNA interaction network. 61
29579224 2019
8
Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights. 61
31236308 2019
9
Lymphangiomatosis of the ileum with perforation: A case report and review of the literature. 61
30992989 2019
10
[Current Therapies in Superficial Malignant Tumors]. 61
28898915 2018
11
Utilizing lymphatic cell markers to visualize human lymphatic abnormalities. 61
28869350 2018
12
Volatile metabonomic profiling in urine to detect novel biomarkers for B-cell non-Hodgkin's lymphoma. 61
29725472 2018
13
Worldwide assessment of healthcare personnel dealing with lymphoedema. 61
29663122 2018
14
Indications for medical compression stockings in venous and lymphatic disorders: An evidence-based consensus statement. 61
28549402 2018
15
Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. 61
29305921 2018
16
Physiotherapeutic rehabilitation of lymphedema: state-of-the-art. 61
30248726 2018
17
Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes. 61
28642594 2018
18
Hispolon as an inhibitor of TGF-β-induced epithelial-mesenchymal transition in human epithelial cancer cells by co-regulation of TGF-β-Snail/Twist axis. 61
29085494 2017
19
Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. 61
28771378 2017
20
Use of Unenhanced MR Lymphography to Characterize Lung Lymphatic Diseases. 61
28639922 2017
21
Reply to "Use of Unenhanced MR Lymphography to Characterize Lung Lymphatic Diseases". 61
28639923 2017
22
In Vivo Molecular Optical Coherence Tomography of Lymphatic Vessel Endothelial Hyaluronan Receptors. 61
28439123 2017
23
Morphological and molecular characteristics of Malayfilaria sofiani Uni, Mat Udin & Takaoka n. g., n. sp. (Nematoda: Filarioidea) from the common treeshrew Tupaia glis Diard & Duvaucel (Mammalia: Scandentia) in Peninsular Malaysia. 61
28427478 2017
24
TNFΔARE Mice Display Abnormal Lymphatics and Develop Tertiary Lymphoid Organs in the Mesentery. 61
28183530 2017
25
Preliminary Evaluation of Virtual Touch Tissue Imaging Quantification for Differential Diagnosis of Metastatic and Nonmetastatic Cervical Lymph Nodes. 61
28127781 2017
26
Fibro-Lipo-Lymph-Aspiration With a Lymph Vessel Sparing Procedure to Treat Advanced Lymphedema After Multiple Lymphatic-Venous Anastomoses: The Complete Treatment Protocol. 61
27404468 2017
27
A LYVE-1/CRSBP-1 Mutation in Inherited Primary Lymphedema. 61
30231303 2017
28
MicroRNA-126a Directs Lymphangiogenesis Through Interacting With Chemokine and Flt4 Signaling in Zebrafish. 61
27789478 2016
29
Interventional Treatment of Pulmonary Lymphatic Anomalies. 61
27993326 2016
30
Analysis of Epstein-Barr virus and cellular gene expression during the early phases of Epstein-Barr virus lytic induction. 61
27625030 2016
31
Lymphatic Vessels in Regenerative Medicine and Tissue Engineering. 61
27142568 2016
32
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. 61
27580273 2016
33
[Application of lymphography in the location and treatment decision of chyle leakage: an analysis of 177 cases]. 61
27029203 2016
34
Lymphatic Vascular Regeneration: The Next Step in Tissue Engineering. 61
26204330 2016
35
[Angiology is moving forward]. 61
27481194 2016
36
Intravital Imaging Reveals Dynamics of Lymphangiogenesis and Valvulogenesis. 61
26785921 2016
37
Hispolon inhibits the growth of estrogen receptor positive human breast cancer cells through modulation of estrogen receptor alpha. 61
26056942 2015
38
Low Lymphatic Pumping Pressure in the Legs Is Associated with Leg Edema and Lower Quality of Life in Healthy Volunteers. 61
26091410 2015
39
cKit Lineage Hemogenic Endothelium-Derived Cells Contribute to Mesenteric Lymphatic Vessels. 61
25772358 2015
40
Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. 61
24965711 2014
41
[EUS-FNA: how to improve biopsy results? An evidence based review]. 61
25198088 2014
42
Long-term outcomes of surgical management for nonmalignant perineal disease. 61
23764084 2013
43
[Lymphangioma and lymphangiectasia]. 61
23688723 2013
44
[Enigmatic lymphatic diseases involving the lung]. 61
23561737 2013
45
[Chest magnetic resonance lymphography]. 61
23597634 2013
46
Pulmonary post-transplant lymphoproliferative disorder with a CT halo sign. 61
24045455 2013
47
PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. 61
23499718 2013
48
[Diagnosis of lymphedema]. 61
23632860 2013
49
Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin. 61
23737816 2013
50
Diffuse pulmonary lymphatic disease presenting as interstitial lung disease in adulthood: report of 3 cases. 61
22982897 2012

Variations for Lymphatic System Disease

Expression for Lymphatic System Disease

Search GEO for disease gene expression data for Lymphatic System Disease.

Pathways for Lymphatic System Disease

GO Terms for Lymphatic System Disease

Cellular components related to Lymphatic System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.97 CD8A CD40LG CD4 CD1E CD1D CD1C
2 extracellular space GO:0005615 9.97 SERPINA3 MIR17 MIR150 CD40LG CD1E CD1D
3 endosome GO:0005768 9.7 UNC13D CD68 CD1E CD1D CD1C CD1B
4 endosome membrane GO:0010008 9.65 CD68 CD1D CD1C CD1B CD1A
5 lysosome GO:0005764 9.43 UNC13D CD68 CD1E CD1D CD1C CD1B
6 external side of plasma membrane GO:0009897 9.32 ICOSLG CD8A CD40LG CD4 CD1E CD1D

Biological processes related to Lymphatic System Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.02 IRF4 ICOSLG CD8A CD4 CD1E CD1D
2 adaptive immune response GO:0002250 9.91 ICOSLG CD4 CD1E CD1C CD1B CD1A
3 immune response GO:0006955 9.91 CD8A CD40LG CD4 CD1E CD1D CD1C
4 regulation of immune response GO:0050776 9.87 ICOSLG CD8A CD40LG CD1D CD1C CD1B
5 T cell activation GO:0042110 9.71 IRF4 ICOSLG CD8A CD4
6 positive regulation of T cell proliferation GO:0042102 9.65 CD40LG CD4 CD1D
7 positive regulation of T cell mediated cytotoxicity GO:0001916 9.55 CD1E CD1D CD1C CD1B CD1A
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.49 IRF4 CD4
9 T cell selection GO:0045058 9.46 CD4 CD1D
10 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.35 CD1E CD1D CD1C CD1B CD1A
11 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.02 CD1E CD1D CD1C CD1B CD1A

Molecular functions related to Lymphatic System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopeptide binding GO:0071723 9.55 CD1E CD1D CD1C CD1B CD1A
2 exogenous lipid antigen binding GO:0030884 9.35 CD1E CD1D CD1C CD1B CD1A
3 endogenous lipid antigen binding GO:0030883 9.02 CD1E CD1D CD1C CD1B CD1A

Sources for Lymphatic System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....